• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Akorn files abbreviated application for FDC

Article

Buffalo Grove, IL-Akorn Inc. has submitted the first abbreviated new drug application with the Office of Generic Drugs on behalf of FDC Ltd., India's second-largest manufacturer and marketer of ophthalmic pharmaceutical products.

Buffalo Grove, IL-Akorn Inc. has submitted the first abbreviated new drug application with the Office of Generic Drugs on behalf of FDC Ltd., India's second-largest manufacturer and marketer of ophthalmic pharmaceutical products.

The proposed drug is an ophthalmic solution that FDC will manufacture in a blow-fill-seal container closure system.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.